Amgen wins court patent ruling over Sandoz biosimilar
The US District Court has decided in favour of Amgen’s Enbrel, ruling over Sandoz’s Erelzi in a patent conflict.
List view / Grid view
The US District Court has decided in favour of Amgen’s Enbrel, ruling over Sandoz’s Erelzi in a patent conflict.
Portable biopharmaceutical drug manufacturers could be the future method of producing the drugs on demand for outbreaks of disease...
People who take immunosuppressants are less likely to develop Parkinson's disease...